Sangamo Therapeutics, Inc is a pharmaceutical company based in the United States of America with an ESG score of 27.1, categorizing it as a medium-risk company. Specializing in genomic medicine, Sangamo Therapeutics is dedicated to developing groundbreaking treatments for serious neurological diseases. The company's pipeline products address a range of issues such as Chronic Neuropathic Pain, Prion Disease, Hemophilia A, Oncology and more. Explore Sangamo Therapeutics for innovative solutions in the field of pharmaceuticals.